经皮腔内肺动脉成形术治疗慢性血栓栓塞性肺动脉高压的有效性与安全性
该前瞻性单臂研究纳入19例CTEPH患者,行56次PTPA治疗。术后24周平均肺动脉压、全肺阻力显著下降,心输出量、6分钟步行距离显著改善,WHO功能分级改善,无死亡,安全性良好。
要点
- PTPA可显著降低CTEPH患者平均肺动脉压和全肺阻力。
- PTPA可改善心输出量、6分钟步行距离及WHO功能分级。
- 围术期咯血及再灌注肺水肿发生率低,无死亡。
核心结论
- PTPA治疗CTEPH安全,可显著改善血流动力学和WHO功能分级。
研究设计与样本
- 前瞻性单臂研究,纳入2017年1月至2019年6月武汉亚洲心脏病医院19例CTEPH患者,男性7例,年龄(56.3±12.5)岁。
主要发现
- 19例患者共接受56次PTPA,累计扩张肺动脉260支,每次扩张(5.14±2.36)支。
- 术后24周平均肺动脉压由(40.11±7.55)mmHg降至(27.53±4.75)mmHg(P<0.001)。
- 术后24周全肺阻力由(13.00±3.56)Wood U降至(5.48±1.56)Wood U(P<0.001)。
- 术后24周心输出量由(3.19±0.63)L/min增至(5.23±0.94)L/min(P<0.01)。
- 术后24周6分钟步行距离由(307.08±129.51)m增至(428.00±112.64)m(P=0.002),NT-proBNP降低(P=0.002),WHO功能分级改善(P<0.001)。
关键数值与推荐
- 随访期内无死亡;4例患者术中发生咯血共7例次,均未导致严重不良后果;1例发生再灌注性肺水肿,治疗后康复。
临床怎么用
- 对于CTEPH患者,PTPA可作为一种改善血流动力学和功能状态的安全介入治疗选择。
局限性
- 本研究为单臂设计,样本量19例,缺乏对照组。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To explore the efficacy and safety of percutaneous transluminal pulmonary angioplasty (PTPA) in patients with chronic thromboembolic pulmonary hypertension (CTEPH). Methods: This prospective single arm study included 19 CTEPH patients (7 male, age(56.3±12.5)years) admitted to Wuhan Asia Heart Hospital from January 2017 to June 2019 and received PTPA interventional therapy. Baseline data, including age, sex, WHO functional class, 6-minute walk distance (6MWD), NT-proBNP, right heart catheterization values, were collected. Patients received single or repeated PTPA. Number of dilated vessels from each patient was analyzed, patients were followed up for 24 weeks and right heart catheterization was repeated at 24 weeks post initial PTPA. All-cause death, perioperative complications, and reperfusion pulmonary edema were reported. WHO functional class, 6MWD, NT-proBNP, right heart catheterization values were compared between baseline and at 24 weeks follow up. Results: Nineteen CTEPH patients received a total of 56 PTPA treatments. The pulmonary artery pressure (mPAP) decreased from (40.11±7.55) mmHg (1 mmHg=0.133 kPa) to (27.53±4.75) mmHg (P<0.001), and the total pulmonary resistance (TPR) decreased from (13.00±3.56) Wood U to (5.48±1.56) Wood U (P<0.001), cardiac output increased from (3.19±0.63) L/min to (5.23±0.94) L/minutes (P<0.01) at 24 weeks post PTPA. The WHO functional class improved significantly (P<0.001), 6MWD increased from (307.08±129.51) m to (428.00±112.64) m (P=0.002), the NT-proBNP decreased at 24 weeks post PTPA (P=0.002). During the follow-up period, there was no death; hemoptysis occurred in 4 patients during the operation, none of which resulted in serious adverse clinical consequences. One patient developed reperfusion pulmonary edema and recovered after treatment. Conclusion: PTPA treatment is safe and can significantly improve the hemodynamics and WHO functional class of patients with CTEPH. 目的: 评估经皮腔内肺动脉成形术(PTPA)治疗慢性血栓栓塞性肺动脉高压(CTEPH)患者的有效性和安全性。 方法: 该研究为前瞻性单臂试验。纳入2017年1月至2019年6月武汉亚洲心脏病医院心外科确诊的CTEPH患者。以明确诊断CTEPH的时间为基线,收集入选患者的基线临床资料,包括年龄、性别、世界卫生组织(WHO)功能分级、6 min步行距离、N末端B型利钠肽原(NT-proBNP)水平以及右心导管测定的血流动力学指标等。患者分次行PTPA,统计每位患者扩张血管数,术后24周随访并复查右心导管。记录手术安全性指标,包括全因死亡、围术期并发症、再灌注肺水肿等。 结果: 共入选患者19例,年龄(56.3±12.5)岁,男性7例。入选患者分别进行了1~7次PTPA,总计56次,累计扩张肺动脉260支,每次扩张血管(5.14±2.36)支。共13例患者测定了6 min步行距离,为(307±130)m。入选患者PTPA术后均自述体力明显改善,尤其以第一次手术后为著。PTPA术后24周,入选患者平均肺动脉压由基线的(40.11±7.55)mmHg(1 mmHg=0.133 kPa)降至(27.53±4.75)mmHg(P<0.001),全肺阻力由基线的(13.00±3.56)Wood单位降低至(5.48±1.56)Wood 单位(P<0.001),心输出量由基线的(3.19±0.63)L/min提高至(5.23±0.90)L/min(P<0.001)。PTPA术后24周,入选患者WHO功能分级明显改善(P<0.001),NT-proBNP明显降低(P=0.002),6 min步行距离由基线的(307.08±129.51)m延长至(428.00±112.64)m(P=0.002)。随访期内无患者死亡;4例患者术中发生咯血,共计7例次,均未导致严重不良后果;1例患者发生再灌注性肺水肿,治疗后康复。 结论: PTPA可改善CTEPH患者的血流动力学及心功能指标,且安全性良好。.
引用
- Jin BW, Zhang GC, Shen QS, et al. [Efficacy and safety of percutaneous transluminal pulmonary angioplasty in patients with chronic thromboembolic pulmonary hypertension]. Zhonghua Xin Xue Guan Bing Za Zhi. 2022. PMID: 35045614. doi:10.3760/cma.j.cn112148-20211202-01040
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。